NS-350

NS-350 is a **preclinical small-molecule drug candidate** reported to be developed by **Neuracle Science** for nervous system disorders, with public aggregator sources describing it as a **TAFA chemokine like family member 5 modulator** or **TAFA5 binder/modulator**. Reported active indications include **Alzheimer's disease** and **sensation disorders**, but detailed primary-source information such as chemical structure, pharmacology, route, formulation, and named clinical studies is not readily identifiable from concrete public sponsor or trial records. Because the available evidence appears limited to secondary drug-database aggregators rather than clear primary-source disclosures, the program should be treated as **poorly characterized and only weakly publicly substantiated**.